Zoloft (Sertraline) Prescribing Guide
Start sertraline at 25-50 mg once daily for most indications, titrate by 25-50 mg weekly as tolerated up to 200 mg maximum, and continue treatment for at least 4-9 months after response. 1
Starting Dose and Titration
The optimal starting dose varies by indication:
- Major Depressive Disorder (MDD), OCD (ages ≥13), PTSD, Social Anxiety, Panic Disorder: Start at 50 mg once daily 1
- Panic Disorder, PTSD, Social Anxiety (alternative): May start at 25 mg once daily if concerned about initial anxiety/agitation 1
- Pediatric OCD (ages 6-12): Start at 25 mg once daily 1
- PMDD: Start at 50 mg once daily (continuous or luteal phase only) 1
Titration schedule: Increase in 25-50 mg increments at 1-2 week intervals for shorter half-life SSRIs like sertraline 2. The 24-hour elimination half-life supports weekly dose adjustments 1. Maximum dose is 200 mg daily for all indications except PMDD (150 mg continuous, 100 mg luteal phase) 1.
Critical prescribing consideration: Starting with a subtherapeutic "test dose" of 25 mg may be advisable since initial adverse effects can include anxiety or agitation, particularly in younger children 2. Research demonstrates that 50 mg daily is as effective as higher doses with fewer side effects and discontinuations 3.
Indications
FDA-approved indications 1:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder (adults and pediatric patients ≥6 years)
- Panic Disorder
- Posttraumatic Stress Disorder
- Social Anxiety Disorder
- Premenstrual Dysphoric Disorder
Important note: While sertraline has substantial empirical support for anxiety disorders in children and adolescents, no specific SSRIs have FDA approval for pediatric anxiety indications 2.
Absolute Contraindications
1:
- Concomitant use with MAOIs (must wait 14 days after stopping MAOI before starting sertraline, and 14 days after stopping sertraline before starting MAOI)
- Concomitant use with pimozide (risk of QTc prolongation)
- Known hypersensitivity to sertraline or excipients
- Oral solution only: Concomitant use with disulfiram (oral solution contains alcohol)
Common Side Effects
Most common (≥5% and twice placebo) 1:
- Nausea (most common reason for discontinuation)
- Diarrhea/loose stool
- Tremor
- Dyspepsia
- Decreased appetite
- Hyperhidrosis (excessive sweating)
- Ejaculation failure
- Decreased libido
Additional common effects 2: dry mouth, headache, somnolence, insomnia, dizziness, vivid dreams, weight changes, fatigue, nervousness, bruxism. Most adverse effects emerge within the first few weeks and are usually mild and transient.
Serious Adverse Effects and Warnings
Black Box Warning: Suicidality
All SSRIs carry a black box warning for suicidal thinking and behavior through age 24 2, 1. The pooled absolute risk is 1% with antidepressants vs 0.2% with placebo (NNH=143 vs NNT=3 for response). Close monitoring is mandatory, especially in the first months of treatment and following dose adjustments 4.
Serotonin Syndrome
Life-threatening condition characterized by mental status changes, neuromuscular hyperactivity (tremors, clonus, hyperreflexia, rigidity), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis, fever) 2. Can occur within 24-48 hours of combining serotonergic agents. Absolute contraindication with MAOIs. Exercise caution when combining with other serotonergic drugs including tramadol, meperidine, methadone, fentanyl, dextromethorphan, triptans, amphetamines, St. John's wort, and illicit drugs 2.
Discontinuation Syndrome
Sertraline is associated with discontinuation syndrome (though less than paroxetine) 2. Symptoms include dizziness, fatigue, myalgias, headaches, nausea, insomnia, paresthesias, anxiety, and agitation. Always taper gradually rather than stopping abruptly 1, 5. Recent evidence suggests hyperbolic tapering to very low doses (much lower than therapeutic minimums) over months minimizes withdrawal symptoms 5.
Behavioral Activation/Agitation
More common in younger children than adolescents, can occur early in treatment or with dose increases 2. Manifests as motor/mental restlessness, insomnia, impulsiveness, disinhibited behavior, or aggression. This supports slow up-titration and close monitoring, particularly in younger children 2.
Other Serious Risks
- Abnormal bleeding (especially with NSAIDs, aspirin, anticoagulants) 2, 1
- Mania/hypomania activation: Screen for bipolar disorder before initiating 1
- QTc prolongation: Use caution in patients with risk factors 1
- Seizures: Use cautiously in seizure disorders 1
- Angle-closure glaucoma: Avoid in untreated narrow angles 1
- Sexual dysfunction 1
Drug Interactions
Sertraline has moderate CYP2D6 inhibition 2. May interact with drugs metabolized by CYP2D6 (reduce dosage of CYP2D6 substrates as needed) 1. However, sertraline has less effect on CYP450 enzymes compared to fluoxetine, paroxetine, and fluvoxamine 2.
Monitor closely with protein-bound drugs (e.g., warfarin) as sertraline is highly protein-bound 1.
Special Populations
Hepatic Impairment
- Mild impairment (Child-Pugh 5-6): Use half the recommended starting and maximum dose 1
- Moderate to severe impairment (Child-Pugh ≥7): Not recommended 1
Pediatric Patients
Safety and effectiveness established only for OCD in children ≥6 years 1. For other conditions in youth, parental oversight is paramount 2. At low doses, youth may require twice-daily dosing 2.
Elderly Patients
Sertraline is preferred in older adults (along with citalopram, escitalopram, mirtazapine, venlafaxine, bupropion) over paroxetine and fluoxetine due to better tolerability 6. No dose adjustment needed based on age alone 7.
Pregnancy
Third trimester use may increase risk for persistent pulmonary hypertension and neonatal withdrawal 1.
Treatment Duration
For first episode of MDD: Continue for at least 4-9 months after satisfactory response 8, 6, 1. For patients with ≥2 episodes, longer duration is beneficial 8.
Expected timeline for response: Statistically significant improvement may occur within 2 weeks, clinically significant improvement by week 6, maximal improvement by week 12 or later 2. This supports slow up-titration to avoid exceeding optimal dose.
Monitoring
Contact within 1-2 weeks of initiation (in-person or telephone) to assess status, therapeutic response, adverse effects, and adherence 4. Continue regular monitoring, especially during first months and after dose changes 4. If inadequate response at 6-8 weeks, modify treatment 8.